{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:52:46Z","timestamp":1762429966927},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1986,1,1]],"date-time":"1986-01-01T00:00:00Z","timestamp":504921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1986]]},"DOI":"10.1007\/bf00613517","type":"journal-article","created":{"date-parts":[[2004,11,24]],"date-time":"2004-11-24T23:23:31Z","timestamp":1101338611000},"page":"419-422","source":"Crossref","is-referenced-by-count":21,"title":["Transdermal delivery of bupranolol: Pharmacodynamics and beta-adrenoceptor occupancy"],"prefix":"10.1007","volume":"31","author":[{"given":"A.","family":"Wellstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"K\ufffdppers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. F.","family":"Pitschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Palm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"30","volume-title":"Betablocker","author":"LF Chasseaud","year":"1978","unstructured":"Chasseaud LF (1978) Pharmacokinetics and metabolism of bupranolol. In: Rahn KH, Schrey A (eds) Betablocker. Urban und Schwarzenberg, M\u00fcnchen Wien Baltimore, pp 30?33"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00498849","volume":"331","author":"AJ Kaumann","year":"1985","unstructured":"Kaumann AJ, Lemoine P (1985) Direct labelling of myocardial beta1-adrenoceptors. Comparison of binding affinity of3H-(--)-bisoprolol with it's blocking potency. Naunyn-Schmiedebergs Arch Pharmacol 331: 27?39","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-2999(80)90462-8","volume":"66","author":"TP Kenakin","year":"1980","unstructured":"Kenakin TP (1980) Effects of equilibration time on the attainment of equilibrium between antagonists and drug receptors. Eur J Pharmacol 66: 295?306","journal-title":"Eur J Pharmacol"},{"key":"CR4","first-page":"242","volume":"9","author":"HO Schild","year":"1957","unstructured":"Schild HO (1957) Drug antagonism and pAx. Pharmacol Rev 9: 242?246","journal-title":"Pharmacol Rev"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00005344-198503000-00006","volume":"7","author":"PH Vlasses","year":"1985","unstructured":"Vlasses PH, Ribeiro LGT, Rotmensch HH, Bondi JV, Loper AE, Hiches M, Dunlay MC, Ferguson RK (1985) Initial evaluation of transdermal timolol: Serum concentrations and beta-blockade. J Cardiovasc Pharmacol 7: 245?250","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00556890","volume":"27","author":"A Wellstein","year":"1984","unstructured":"Wellstein A, Palm D, Wiemer G, Sch\u00e4fer-Korting M, Mutschler E (1984) Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma. Eur J Clin Pharmacol 27: 545?553","journal-title":"Eur J Clin Pharmacol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00547412","volume":"29","author":"A Wellstein","year":"1985","unstructured":"Wellstein A, Palm D, Pitschner HF, Belz GG (1985) Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol 29: 131?147","journal-title":"Eur J Clin Pharmacol"},{"key":"CR8","unstructured":"Wellstein A, Palm D, Belz GG (1986) Beta-adrenoceptor subtype mediated effects in man in comparison to in vitro beta1- and beta2-adrenoceptor occupancy. Naunyn-Schmiedeberg's Arch Pharmacol 332 [Suppl]: R 78"},{"key":"CR9","first-page":"123","volume-title":"Beta-blocker","author":"C Werning","year":"1978","unstructured":"Werning C (1978) Erfahrungen mit Bupranolol (Betadrenol) in der Hochdrucktherapie. In: Rahn KH, Schrey A (eds) Beta-blocker. Urban und Schwarzenberg, M\u00fcnchen Wien Baltimore, pp 123?125"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00613517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00613517\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00613517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T23:42:42Z","timestamp":1554421362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00613517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1986]]}},"alternative-id":["BF00613517"],"URL":"https:\/\/doi.org\/10.1007\/bf00613517","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986]]}}}